A Randomized, Open Label, Multicenter Study of Cabazitaxel Versus an Androgen Receptor (AR)-Targeted Agent (Abiraterone or Enzalutamide) in mCRPC Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD)

Primary Objective:

To compare the radiographic progression-free survival (rPFS) (using Response Evaluation
Criteria in Solid Tumors [RECIST] 1.1 for tumor lesions and Prostate Cancer Working Group 2
(PCWG2) criteria for bone scan lesions or death due to any cause) with chemotherapy
(cabazitaxel plus prednisone, Arm A) versus Androgen Receptor (AR)-targeted therapy
(enzalutamide or abiraterone acetate plus prednisone, Arm B) in mCRPC participants who have
been treated with docetaxel and who had disease progression while receiving AR-targeted
therapy within 12 months of AR treatment initiation (less than or equal to [<=]12 months,
either before or after docetaxel).

Secondary Objective:

- To compare efficacy for:

- Prostate-specific antigen (PSA) response rate and time to PSA progression (TTPP).

- Progression-free survival (PFS).

- Overall survival (OS).

- Tumor response rate and duration of tumor response.

- Pain response and time to pain progression.

- Symptomatic skeletal event (SSE) rate and time to occurrence of any SSE.

- Health status and Health-related Quality of Life (HRQOL).

- To evaluate the correlation of a signature of resistance to AR-targeted agents with
clinical outcome via the analysis of circulating tumor cell (CTC) phenotypes as well as
expression and localization of proteins including AR isoforms in CTCs.

- To evaluate safety in the 2 treatment arms.